1 Cellular and organ changes lead to serious complications such as heart disease, stroke, eye disease (including retinopathy), kidney disease, peripheral vascular disease, nerve damage, foot problems, increased infection risk, poor wound healing and gum disease
Type 2 Diabetes & Obesity (Unified Protocol) Starting Dose: 0.25 mg once weekly Titration: Increase every 4 weeks as tolerated ( 0.5 mg 1.0 mg 1.7 mg 2.4 mg) Common Dose: 1.02.0 mg weekly Maximum Dose: 2.4 mg weekly Recommended Dosage Table Possible Adverse Reactions Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain (especially during titration) Hypoglycemia: low risk alone
Use extreme caution and monitor glucose closely
Unlike semaglutide-based medications such as Ozempic and Wegovy, which target only GLP-1, tirzepatide targets both pathways at once